Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px
Document › Details

CureVac AG. (5/19/17). "Press Release: CureVac to Present at Upcoming International Investor Conferences". Tübingen.

Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 UBS (Group)
Products Product UBS Global Healthcare Conference 2017 New York
  Product 2 BioEquity Europe 2017 Paris
Index terms Index term CureVac–UBS: investor conference, 201705 supply service CureVac presents at UBS Global Healthcare Conference NY
  Index term 2 CureVac–Informa: investor conference, 201705 supply service CureVac presents at BioEquity Europe 2017 in Paris
Persons Person Kemula, Pierre (CureVac 201610– CFO before Pixium Vision + Ipsen + Roland Berger)
  Person 2 Haas, Franz-Werner (CureVac 201206– Chief Corporate Officer before Sygnis + Lion BIoscience)
     


CureVac AG, the most clinically ad-vanced mRNA company, today announced that the company will present at two upcoming international investor conferences: UBS 2017 Global Healthcare Confer-ence in New York, NY; and Bio€quity Europe in Paris, France.

Executives from CureVac will provide an overview of the company’s business, in-dustry-leading mRNA technology platform, and clinical-stage product pipeline during each presentation and will be available to participate in one-on-one meet-ings with investors who are registered to attend each conference.


Event: UBS 2017 Global Healthcare Conference
Presenter: Pierre Kermula, Chief Financial Officer
Date: Monday, May 22, 2017
Time: 2:30 – 3:00 pm, ET
Location: Grand Hyatt, New York, NY – Ballroom IV


Event: Bio€quity Europe
Presenter: Dr. Franz-Werner Haas, Chief Corporate Officer
Date: Monday, May 22, 2017
Time: 3:40 – 4:00 pm, CET
Location: Marriott Rive Gauche, Paris, France– Forum EF, Level -1


About CureVac AG

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The fully integrated biopharmaceutical Ccompa-ny has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the de-velopment of cancer therapies, prophylactic vaccines and molecular therapies.

Since its inception, strongly backed by SAP founder Dietmar Hopp’s dievini CureVac has received approximately $370 million (€355 million) in equity invest-ments including an investment of the Bill & Melinda Gates Foundation of $ 52million in 2015. CureVac has entered into various collaborations with multina-tional corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.
In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac started the establishment and construc-tion of industrial scale production facilities.

For more information, please visit www.curevac.com


***

Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756
verena.lauterbach@curevac.com

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694
amielach@tiberend.com

   
Record changed: 2017-07-02

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 41 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px